Search Bar & Filters
Found 38 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and effectiveness of the FDA-approved VARIPULSE catheter system for pulmonary vein isolation PVI in treating people with symptomatic paroxysmal atrial fibrillation PAF. This study focuses on participants who are candidates for catheter ablation due to symptoms and have not responded well to certain antiarrhythmic drugs. Participants will undergo electrophysiology mapping and pulsed field ablation PFA using the VARIPULSE catheter combined with the TRUPULSE generator. This treatment is designed to isolate pulmonary veins to manage atrial fibrillation symptoms. The study observes outcomes both shortly after the procedure and over the long term. During the study, participants will be monitored for early adverse events within 7 days after the ablation procedure. They will also be followed for freedom from documented atrial tachyarrhythmia episodes from about 2 months up to 3 years after treatment. Assessments include clinical evaluations and adherence to follow-up testing to understand the devices safety and effectiveness over time.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.
Actively Recruiting
Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.
Actively Recruiting
Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.
1-10 of 38
1